课题基金 / 基金详情

INHIBITION OF PAPILLOMAVIRUSES IN ORAL EPITHELIUM

INHIBITION OF PAPILLOMAVIRUSES IN ORAL EPITHELIUM
口腔上皮中乳头状病毒的抑制
批准号:
2015134
负责人:
EDWARD J. SHILLITOE
金额:
$20.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-02-01 至 2001-01-31

项目摘要

项目成果

EDWARD J. SHILLITOE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Human papillomaviruses (HPVs) are believed to be important in the etiology of oral cancer. They are present in many of the tumors and can transform oral epithelial cells to a malignant phenotype. In the current grant period we have developed ribozymes which cut the RNA transcript of HPV-18, and which inhibit the malignant phenotype of a cervical cancer cell line that expresses HPV-18. In the next grant period we will expand upon this work to achieve three aims. Specific Aim 1 will be to broaden the spectrum of anti-HPV ribozymes. This will be done by making new ribozymes that inhibit HPV that are found in over 60% of oral cancers. A virus vector will be made which expresses all three of the ribozymes in a single construct. The functions of this multi-ribozyme vector will be opitmized so as to express the strongest anti-HPV activity. Specific Aim 2 will be to use the ribozymes to study the role of HPVs in the growth of oral cancer cells. A large panel of oral cancer cells and other cells will be examined. We will test the hypothesis that the HPVs express the viral E6 and E7 proteins, which in turn block the activity of the cellular p53 and RB proteins, thus preventing programmed death of the cancer cells. Specific Aim 3 will be to find if the anti-HPV ribozymes are active as gene therapy agents against oral cancer. Oral cancers will be removed from patients and transplanted to nude mice. There they will be treated with the virus vector that express anti-HPV ribozymes. The anti-cancer effects will be used to predict the effects of this form of gene therapy on patients with oral cancer. This project will answer basic questions regarding the etiology of oral cancer and will contribute to the development of new treatments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Treatment of oral cancer by herpes simplex virus
  • 批准号:
    7385457
  • 项目类别:
  • 资助金额:
    $23.55万
  • 财政年份:
    2008
  • 负责人:
    EDWARD J. SHILLITOE
  • 依托单位:
Treatment of oral cancer by herpes simplex virus
  • 批准号:
    7568856
  • 项目类别:
  • 资助金额:
    $19.63万
  • 财政年份:
    2008
  • 负责人:
    EDWARD J. SHILLITOE
  • 依托单位:
HERPES SIMPLEX VIRUS IN THE TREATMENT OF ORAL CANCER
  • 批准号:
    6634661
  • 项目类别:
  • 资助金额:
    $25.72万
  • 财政年份:
    2000
  • 负责人:
    EDWARD J. SHILLITOE
  • 依托单位:
HERPES SIMPLEX VIRUS IN THE TREATMENT OF ORAL CANCER
  • 批准号:
    6516558
  • 项目类别:
  • 资助金额:
    $25.72万
  • 财政年份:
    2000
  • 负责人:
    EDWARD J. SHILLITOE
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: